The UK government has published its response to the consultation reviewing the new Statutory Scheme. Craig Smith and Rob McCaskill at Decisive Consulting Ltd take a closer look at the key decisions proposed for the UK's new Statutory Scheme.

Late last week, German Health Minister Karl Lauterbach unveiled major reforms across the pharmaceutical landscape that include changes in the statutory rebates and implementing confidential discounts.

A new 5-year medicine pricing framework has been agreed upon in the UK: Take a closer look at the UK's new VPAG agreed by the government, NHS England, and the Association of the British Pharmaceutical Industry (ABPI).

Despite the fact that CEAs are currently focused on listed products, if cost-effectiveness takes more of a prominent role in the HTA process at launch this could result in potential new challenges for pricing and market access in Japan.

In July, the Health Ministry in Germany published a draft of a new bill referred to as the Act for Financial Stability of the Public Health Insurance (GKV-FinStG). Despite strong opposition and critique raised by almost all stakeholders, the draft law was agreed upon by the Federal Cabinet on July 27th.

How has the role of Access within the life science sector changed? How has this altered the capabilities needed to succeed?

Individuals who take out private health insurance has increased in Ireland from 21% in 2008 to roughly 40% in 2022. How does this drastic shift to private healthcare reflect the government’s lack of funding towards new, more expensive treatments that have greater clinical efficacy?